Role of hyaluronic acid intrauterine injection in the prevention of Asherman’s syndrome in women undergoing uterine septum resection: An RCT by Zahra Ghanadzadeh Tafti, Seiede et al.
International Journal of Reproductive BioMedicine
Volume 19, Issue no. 4, https://doi.org/10.18502/ijrm.v19i4.9060
Production and Hosting by Knowledge E
Original Article
Role of hyaluronic acid intrauterine injection
in the prevention of Asherman’s syndrome in
women undergoing uterine septum resection:
An RCT
Seiede Zahra Ghanadzadeh Tafti1 M.D., Atiye Javaheri1 M.D., Razieh Dehghani
Firoozabadi2 M.D., Samane Kabirpour Ashkezar1 M.D., Hossein Falahzadeh
Abarghouei3 Ph.D.
1Department of Obstetrics and Gynecology, Faculty of Medicine, Shahid Sadoughi University of
Medical Sciences, Yazd, Iran.
2Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid
Sadoughi University of Medical Sciences, Yazd, Iran.
3Department of Biostatistics, Faculty of Health, Shahid Sadoughi University of Medical Sciences,
Yazd, Iran.
Abstract
Background: Adhesion due to intrauterine surgery such as septal resection associated
with damaged endometrium can increase the risk of Asherman’s syndrome. The main
goal of treatment in this syndrome is to repair the damaged endometrium for creating
a physiological pregnancy.
Objective: To investigate the effect of intrauterine injection of hyaluronic acid on the
prevention of Asherman’s syndrome in women undergoing uterine septum resection.
Materials and Methods: In this double-blind randomized clinical trial, 65 women
undergoing the uterine septum resection were divided into two groups; the case group
(n = 34) and the control group (n = 31). Immediately after the septal resection with
a resectoscope, 1cc of hyaluronic acid gel in the case group and 1cc normal saline
solution as a placebo in the control group was injected into the uterine cavity. After
two months, existence of intrauterine adhesions in the both groups was examined by
the hysteroscope and assessment of menstrual patterns, according to the American
Society for Reproductive Medicine criteria.
Results: Our results showed that after intervention, the incidence of Asherman’s
syndrome in the control group was higher than the case group (p = 0.012). In the case
group, only four women had poor adhesion (Asherman’s syndrome) at the end of the
study, while the rest of them were free of any adhesions in the uterine cavity. In the
control group, however, only 19 were free of intrauterine adhesions and 12 had mild
symptoms.
Conclusion: The results of the study exhibited the hyaluronic acid capacity to reduce
the risk of Asherman’s syndrome in womenwith endometrial damage following a septal
resection surgery.
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1. Introduction
Asherman’s syndrome, or intrauterine adhesion,
is an acquired disease involving intrauterine
adhesions that occur usually as a result of
pregnancy, childbirth, infection, or uterine
surgery such as myomectomy or correction of
uterine abnormalities (e.g., intrauterine septum
or bicornuate uterus) (1-3). If the Asherman’s
syndrome causes infertility and amenorrhea,
treatment is necessary. In such cases, surgical
treatment is performed by cutting and removing the
adhesions using hysteroscopic and laparoscopic
methods. Complications of hysteroscopic surgery
include bleeding, uterine perforation, and pelvic
infection. However, in some patients, infertility is
not treated even after the treatment of Asherman’s
syndrome (intrauterine adhesions) (4, 5). The main
goal of treatment in this syndrome is to repair
the damaged endometrium as well as create a
physiological condition suitable for pregnancy.
Recently, drugs containing 100% hyaluronic acid
have been used to treat adhesions.
Hyaluronic acid is an organic compound also
known as hyaluronan. Polymeric hyaluronic acid
is composed of D-glucuronic acid and N-acetyl
glucosamine. Hyaluronic acid chains can be
composed of 25,000 units or more, and the
molecular weight of these chains varies between
5,000 and 20 million daltons. Hyaluronic acid is
made by an enzyme called hyaluronan synthase.
At least three types of hyaluronan synthetic
enzyme (HAS) are available to humans: HAS1,
HAS2, and HAS3. Types 1 and 2 produce high
molecular-weight hyaluronic acids while type three
generates light hyaluronic acids. Hyaluronic acid is
degenerated by an enzyme called hyaluronidase
(6, 7). Its anti-adhesive effect depends on the
molecular weight and concentration of the
product. The gel containing 100% hyaluronic
acid, which is very sticky and acts as a mechanical
barrier in the uterine cavity, prevents adhesion.
Adhesions usually develop from the third to the
fifth day after the surgery and the hyaluronic acid
composition remains in place for seven days after
which it is completely absorbed. Several studies
have investigated the effect of hyaluronic acid
compounds in preventing adhesions and the
development of Asherman’s syndrome following
manipulation of the uterine cavity in animal and
human models and have reported the capacity of
the hyaluronic acid gel in keeping the uterine walls
in place for 72 hr. Hysteroscopic studies have also
shown a statistically significant decrease in the
intrauterine adhesions a few months following the
surgery (8-15).
Due to the features mentioned for this
compound, this study was designed and
conducted to investigate the use of hyaluronic
acid in the prevention of Asherman’s syndrome in
women undergoing uterine septum resection.
2. Materials and Methods
This randomized double-blind clinical trial was
performed on women, aged 15-45 yr, that were
referred to the Shahid Sadoughi Hospital in
Yazd, Iran for septal resection surgery between
November and December 2019. Participants were
primarily divided into two groups of case (n = 34)
and control (n = 31) using random number tables.
Our exclusion criteria comprised body mass index
> 35 kg/m2, menopause, pregnancy, history of
cervical cancer, coagulation disorders, and severe
pelvic infections.
The sample size was estimated to be 80 (40 in
each group), considering the significance level of
5%, the power of 80%, based on a previous similar
article (16), and to reach the difference of 20% for
the degree of adhesion in the two groups.
𝑛 =
(𝑍(1− 𝛼2 ) + 𝑍1−𝛽)
2[𝑃𝐴(1 − 𝑃𝐴) + 𝑃𝐵(1 − 𝑃𝐵)]
(𝑃𝐴 − 𝑃𝐵)2
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All participants underwent uterine septal
resection using a rectoscope. In the case group,
1𝑐𝑐 of hyaluronic acid gel (Humedix Co., Korea) and
in the controls, 1𝑐𝑐 of normal saline solution
as a placebo was injected into the uterine
cavity, immediately after surgery. Hyaluronic
acid gels and normal saline were prepared and
coded in similar syringes with the same volume,
and one Obstetrics and Gynecology resident
performed the injections. All participants, project
executives, and researchers were blinded to
the type of solution and group classification.
Two groups then underwent hormone therapy
with estrogen conjugate 1.25 mg/day and
medroxyprogesterone 5 mg/day orally from
day 14 to 24 of the menstrual cycle for two
months. Two months after the intervention,
intrauterine adhesion score was examined
through hysteroscopy and clinical signs (menstrual
pattern) were classified into mild, moderate, and
severe types according to the American Society
for Reproductive Medicine (ASRM) criteria as
following:
(i) Mild: Involvement of < 1/3 of the uterine cavity
and the presence of delicate adhesions with a
regular menstrual pattern.
(ii) Moderate: Involvement of 1/3-2/3 of the
uterine cavity with delicate-to-moderate adhesions
with most hypomenorrhea.
(iii) Severe: Involvement of > 2/3 of the uterine
cavity and the presence of thick bands of adhesion
with amenorrhea.
In the beginning of the study, basic
characteristics of the participants including age,
gravity, number of live births, abortion, stillbirth,
and the menstrual pattern were recorded in
the data collection form. Finally, the number
of menstrual days and volume of menstrual
bleeding before and after the intervention, as well
as the incidence and severity of Asherman’s
syndrome was investigated and compared
between the groups in terms of adhesion
score.
2.1. Ethical considerations
All participants were orally informed about the
purpose of this study and the procedure thereof,
and a written informed consent was obtained from
each one of them prior to the study. In addition,
the research proposal was reviewed and approved
by the Ethics Committee of Shahid Sadoughi
University of Medical Sciences, Yazd, Iran (Code:
IR.SSU.MEDICINE.REC.1398.201).
2.2. Statistical analysis
Data were entered into the SPSS software,
version 22 (Statistical Package for the Social
Sciences, version 22.0, SPSS Inc., Chicago,
Illinois, USA). The mean ± standard deviation,
and variance of the variables were calculated
and compared using analytical tests including
Student’s t test and Chi-square test between the
two groups. The P-value < 0.05 was considered
as significant.
3. Results
Of the 80 participants who initially entered into
the study according to the mentioned inclusion
and exclusion criteria, 9 from the case group and
6 from the control group, due to not referring at
the time of follow-up were lost subsequently and,
therefore, 65 women were included in the final
analysis (34 in the case group and 31 in the control
group) (Figure 1). No significant difference was
observed between the two groups in terms of age,
gravidity, number of miscarriages, and stillbirths
(Table I).
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Additionally, the two groups were not
significantly different as for menstrual patterns
(number of days and volume ofmenstrual bleeding)
before and after the intervention. The menstrual
patterns of the participants in two groups were
as follows: 21 (61.8%) women had a regular
menstruation pattern in both groups, while 13
(38.2%) women in the case group and 10 (32.3%)
in the control group had an irregular pattern (p =
0.40). In addition, in the two groups, the number
of women with regular menstruation was higher
than those with an irregular one. The volume of
menstrual bleeding and the number of menstrual
days before and after the intervention did not show
a statistically significant difference between the
two groups (Table II).
As illustrated in Table II, the incidence of
Asherman’s syndrome in the case group receiving
hyaluronic acid was significantly lower than the
controls. In the case group, only four women had
poor adhesion at the end of the study, while
the rest of them were free of any adhesions
in the uterine cavity (Asherman’s syndrome). In
the control group, however, only 19 were free of
intrauterine adhesions and 12 had mild symptoms.
None of the individuals in the case group reported
any side effects of using hyaluronic acid (such as
allergic reaction).
Assessed for eligibility (n = 80) 
Excluded (n = 80) 
● Not meeting inclusion criteria (n = 0) 
● Declined to participate (n = 0) 
● Other reasons (n = 0) 
Analysed (n = 31) 
Allocated to the case group (Hyaluronic acid gel 
injection) (n = 40) 
● Received allocated intervention (n = 40) 
Lost to follow-up (n = 6) 
● Not referring at the time of follow-up (n = 6) 
Allocated to the control group (Normal saline solution 
injection) (n = 40) 
● Received allocated intervention (n = 40) 




Randomized (n = 80) 
Enrollment 
Lost to follow-up (n = 9) 
● Not referring at the time of follow-up (n = 9) 
 
Figure 1. Consort flowchart of the studied participants.
Table I. Comparison of demographic characteristics in the two groups
Variables Case group (n = 34) Control group (n = 31) P-value
Age (Yr)* 33.50 ± 5.01 34.00 ± 5.36 0.699
Gravidity** 1.83 ± 2.27 (3#) 1.80 ± 1.94 (4#) 0.787
Live birth* 1.17 ± 0.39 1.25±0.45 0.633
Abortion* 2.50 ± 1.31 2.00±0.50 0.294
Stillbirth* 2.83 ± 1.72 1.80 ± 1.23 0.182
Menstrual pattern**
Regular 21 (61.76%) 21 (67.74%)
Irregular 13 (38.24%) 10 (32.26%)
0.79
*Data presented as Mean ± SD, Student’s t test, **Data presented as n (%), Chi-square test, #Interquartile range
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Table II. Comparison of the number of days, the volume of menstrual bleeding, and the incidence of Asherman’s syndrome in the
two study groups
Variables Case group (n = 34) Control group (n = 31) P-value
Menstrual bleeding pattern before the intervention*
Hypomenorrhea 5 (14.70) 3 (9.68)
Normal menstruation 23 (67.65) 22 (70.97)
Hypermenorrhea 6 (17.65) 6 (19.35)
0.825𝑎
Menstrual bleeding pattern after the intervention*
Hypomenorrhea 5 (14.70) 3 (9.68)
Normal menstruation 23 (67.65) 22 (70.97)
Hypermenorrhea 6 (17.65) 6 (19.35)
0.825𝑎
Days of the menstrual cycle**
Before intervention 6 ± 0.92 6.06 ± 1.06 0.794𝑏
After intervention 5.97 ± 0.94 6.06 ± 1.06 0.706𝑏
Asherman’s syndrome*
No intrauterine adhesions 30 (88.2) 19 (61.3)
Poor intrauterine adhesions 4 (11.8) 12 (38.7)
0.012𝑎
*Data presented as n (%). **Data presented as Mean ± SD. 𝑎Chi-square test, 𝑏Student’s t test, Hypomenorrhea: < 20 ccs
vaginal bleeding in one menstrual cycle, Normal menstruation: 20-80 cc of vaginal bleeding in one menstrual cycle, and
Hypermenorrhea: > 80 ccs of vaginal bleeding in one menstrual cycle
4. Discussion
Uterine septum is one of the most common
congenital abnormalities in women, associated
with obstetric and fertility problems (17). In this
study, the effect of hyaluronic acid intrauterine
injection on the prevention of Asherman’s
syndrome in 65 women undergoing uterine
septum resection was investigated. Evidenced by
the results, intrauterine injection of hyaluronic acid
reduced the incidence of Asherman’s syndrome
in the case group than the controls with no
reported complications. Acunzo and co-workers
in a randomized controlled trial identified that
hyaluronic acid reduces the development of
intrauterine adhesions following surgery and
is likely to be associated with a reduction in
severe adhesions (15). Hokker and colleagues
also assessed the effect of hyaluronic acid
on the prevention of Asherman’s syndrome
after dilatation and curettage (D & C). Their
results revealed that the use of hyaluronic
acid after D&C for abortion in women with at
least one previous history of D&C reduces the
incidence and severity of uterine adhesions
but fails to eliminate the process of adhesion
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formation (18). Our study too, in line with this,
indicated the significant effect of hyaluronic acid
in reducing uterine adhesions. In a study by
Guida and others performed on 130 patients
in two groups (n = 65/each), the significant
effect of hyaluronic acid after a three-month
follow-up was observed in the intervention
group. They described hyaluronic acid as
a suitable and absorbable substance that
provides an effective and safe strategy for
improving women’s health by reducing the
need for re-intervention after hysteroscopic
surgery (19). The two-month follow-up of
the present study also confirms this claim.
Furthermore, Mais and colleagues in their study
on the reduction of postoperative adhesions
with an injection of the hyaluronic gel after
myomectomy with the laparoscopic method,
being in line with the findings of the present
study, reported that this method reduces the
rate of adhesion and is safe and harmless
(14).
In a randomized clinical trial on 84 women,
the effect of hyaluronic acid was examined
after Asherman’s syndrome treatment. A
follow-up hysteroscopy, three months after
the surgery showed a significant reduction
in intrauterine adhesions subsequent to the
hyaluronic acid injection (14%) compared with
the control group (32%) (20). Our study also
demonstrated a significant effect similar to
the case group. Researchers also believe that
hyaluronic acid can be helpful in preventing
the side effects of traditional anti-adhesives
such as IUDs or foley catheters (21, 22). The
results of the present study as well as several
similar investigations reveal that the use of
hyaluronic acid injected into the uterine cavity
bears the potential to significantly prevent
Asherman’s syndrome in cases of endometrial
damage.
5. Conclusion
Intrauterine injection of hyaluronic acid in
women under uterine septum resection can
significantly reduce the risk of Asherman’s
syndrome and is a safe method for the prevention
of Asherman’s syndrome.
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